Kynam Capital Management, LP - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 180 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2021. The put-call ratio across all filers is 0.46 and the average weighting 0.3%.

Quarter-by-quarter ownership
Kynam Capital Management, LP ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2023$88,064,000
-0.2%
3,200,000
+23.1%
14.40%
+18.7%
Q2 2023$88,218,000
+74.0%
2,600,000
+84.5%
12.13%
+85.3%
Q1 2023$50,712,047
-29.1%
1,409,451
-12.2%
6.55%
-40.4%
Q4 2022$71,552,232
+59.1%
1,605,390
+0.3%
10.98%
+15.8%
Q3 2022$44,980,000
+36.3%
1,600,127
+16.1%
9.48%
+12.5%
Q2 2022$33,002,000
+28.7%
1,378,659
+83.1%
8.43%
+1.3%
Q1 2022$25,648,000
+192.8%
753,034
+232.1%
8.32%
+77.7%
Q4 2021$8,761,000226,7264.68%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q4 2021
NameSharesValueWeighting ↓
ACUTA CAPITAL PARTNERS, LLC 1,017,524$20,961,0007.56%
Octagon Capital Advisors LP 561,398$11,565,0004.36%
COMMODORE CAPITAL LP 369,951$7,621,0003.04%
Opaleye Management Inc. 985,000$20,291,0002.98%
VR Adviser, LLC 1,240,610$25,557,0002.77%
TSP Capital Management Group, LLC 359,229$7,400,0002.61%
RTW INVESTMENTS, LP 3,908,947$80,524,0001.26%
Ghost Tree Capital, LLC 250,000$5,150,0001.21%
Tri Locum Partners LP 196,672$4,051,0001.00%
Redmile Group, LLC 3,387,788$69,788,0000.98%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders